Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Phil Ambery: Next-Generation Endothelin Therapeutics Renew Interest in a Proven Pathway
Phil Ambery/LinkedIn
Jun 21, 2026, 08:04

Phil Ambery: Next-Generation Endothelin Therapeutics Renew Interest in a Proven Pathway

Phil Ambery, Scientific Advisory Board Member at PTEN Research, shared a post on LinkedIn about a recent article by Anthony P. Davenport, published in Canadian Journal of Physiology and Pharmacology, adding:

“As we get to the last lap of the ZENITH High proteinuria study, a review article with our colleagues and collaborators at University of Cambridge detailing the great promise in targeting endothelin biology.”

Title: Next-generation therapeutics and renaissance of legacy drugs targeting the endothelin system

Authors: Anthony P. Davenport, Majid Anwar, Rhoda E. Kuc, Lena Brynne, Anne-Kristina Mercier, Magnus Åstrand, Peter J Greasley, Philip Ambery, Janet J. Maguire

Phil Ambery: Next-Generation Endothelin Therapeutics Renew Interest in a Proven Pathway

Stay updated on all scientific advances Hemostasis Today.

Anne-Kristina Mercier Anthony P. Davenport Canadian Journal of Physiology and Pharmacology Endothelin Health Hematology Hemostasis Hemostasis News Hemostasis Today Janet J. Maguire Lena Brynne Magnus Åstrand Majid Anwar Medicine Peter J Greasley Phil Ambery Philip Ambery Rhoda E. Kuc ZENITH High proteinuria study
NewsFeed